DWM
CRBP icon

Doyle Wealth Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Doyle Wealth Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1
Closed – – 307
2019
Q2 		$0 Buy
+1
New +$214 ﹤0.01% 845
2019
Q1 		– Sell
-1
Closed – – 297
2018
Q4 		$0 Buy
+1
New +$200 ﹤0.01% 858

Other funds holding CRBP

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Doyle Wealth Management's CRBP Position: Q3 2019 in Review

Doyle Wealth Management sold out of Corbus Pharmaceuticals (CRBP) in Q3 2019, closing a stake of 1 share.

Doyle Wealth Management first reported a position in CRBP in Q4 2018 and held it in 2 quarters. The position peaked at $0 in Q2 2019. 103 funds tracked by Wall St. Rank hold CRBP as of Q3 2019.

  • Doyle Wealth Management reported no remaining Corbus Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Doyle Wealth Management sold 1 Corbus Pharmaceuticals share in Q3 2019.
  • Doyle Wealth Management first reported a position in Corbus Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Doyle Wealth Management's Corbus Pharmaceuticals position peaked at $0 in Q2 2019.
  • 103 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2019.

Based on Doyle Wealth Management's 13F filing for Q3 2019, filed 5 Nov 2019.